Practical Guidance for the Multidisciplinary Team on Therapeutics Targeting Protein Degradation Pathways in NHL

Learn more about cereblon E3 ligase modulators (CELMoDs) in the treatment of patients with non-Hodgkin lymphoma including available efficacy and safety data and ongoing clinical trials investigating these agents by attending a local live workshop, downloading the associated slideset, and reviewing an expert-authored commentary on frequently asked questions on this topic.

Share

Program Content

Activities

CELMoDs in NHL
Practical Guidance for the Multidisciplinary Team on Therapeutics Targeting Protein Degradation Pathways in NHL
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 13, 2024

Expires: September 12, 2025

Faculty

cover img faculity

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

cover img faculity

Brad Kahl, MD

Professor of Medicine
Washington University in St Louis
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb